title: Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.
abstract: OBJECTIVE
  This 6-week trial assessed the efficacy, tolerability, and safety of the investigational psychopharmacologic agent asenapine versus placebo and risperidone in patients with acute schizophrenia (DSM-IV criteria).
  
  
  METHODS
  In a study conducted from August 2001 to May 2002, patients were randomly assigned to receive sublingual asenapine 5 mg b.i.d., placebo b.i.d., or oral risperidone 3 mg b.i.d. The primary outcome measure was improvement from baseline in Positive and Negative Syndrome Scale (PANSS) total score. Secondary outcomes included changes in Clinical Global Impressions-Severity of Illness (CGI-S) score and scores on PANSS positive, negative, and general psychopathology subscales.
  
  
  RESULTS
  The intent-to-treat population comprised 174 patients who received >or= 1 dose of study drug and >or= 1 postbaseline assessment. At study end or last observation, mean improvements on PANSS total, negative subscale, and general psychopathology subscale scores were all significantly greater with asenapine than with placebo (p < .005, p = .01, and p < .005, respectively). Compared with placebo, improvements on CGI-S and PANSS positive subscale scores were significantly greater with both asenapine (p < .01 and p = .01) and risperidone (p < .005 and p < .05). Overall incidence rates of adverse events were comparable for asenapine and placebo, whereas risperidone was associated with substantial weight gain and prolactin elevation.
  
  
  CONCLUSIONS
  Asenapine was effective and well tolerated in patients with acute schizophrenia and may provide a new option for control of negative symptoms.
authors.affiliation: Department of Psychiatry and Human Behavior, University of California, Irvine, Brain Imaging Center, CA 92697-3960, USA. sgpotkin@uci.edu
authors.forename: Steven G
authors.initials: SG
authors.lastname: Potkin
authors.forename: Miriam
authors.initials: M
authors.lastname: Cohen
authors.forename: John
authors.initials: J
authors.lastname: Panagides
mesh_terms: D000208:Acute Disease; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D039721:Diagnostic and Statistical Manual of Mental Disorders; D003986:Dibenzocycloheptenes; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006576:Heterocyclic Compounds, 4 or More Rings / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010349:Patient Compliance / Q000706:statistics & numerical data; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012720:Severity of Illness Index
chemical_list: D014150:Antipsychotic Agents; D003986:Dibenzocycloheptenes; D006576:Heterocyclic Compounds, 4 or More Rings; C522667:asenapine; D018967:Risperidone